Literature DB >> 27335363

Case of relentless chronic phase of chronic myeloid leukaemia.

Onyee Chan1, Hao Chen2, Ravitharan Krishnadasan3, Faiz Anwer3.   

Abstract

Initial treatment of chronic phase chronic myeloid leukaemia is straightforward in today's era of tyrosine kinase inhibitors. However, managing refractory cases remain a major challenge due to the multiple factors that can influence decision-making, including medication tolerance, disease burden, mutation status, comorbidities, availability of donor, and fitness for an ablative conditioning. We report a male patient presenting with chronic phase chronic myeloid leukaemia who was treated with 5 different tyrosine kinase inhibitors either due to intolerance and/or failed response. He subsequently received 2 haploidentical haematopoietic stem cells transplants before achieving complete remission. This case highlights various treatment options, need for vigilant disease monitoring, and the possibility of complete positive response even after many lines of therapy failure. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27335363      PMCID: PMC4932415          DOI: 10.1136/bcr-2016-215370

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  15 in total

Review 1.  The biology of chronic myeloid leukemia.

Authors:  S Faderl; M Talpaz; Z Estrov; S O'Brien; R Kurzrock; H M Kantarjian
Journal:  N Engl J Med       Date:  1999-07-15       Impact factor: 91.245

2.  Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update.

Authors:  A Bacigalupo; A Dominietto; A Ghiso; C Di Grazia; T Lamparelli; F Gualandi; S Bregante; M T Van Lint; S Geroldi; S Luchetti; R Grasso; S Pozzi; N Colombo; E Tedone; R Varaldo; A M Raiola
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 3.  The role of hematopoietic stem cell transplantation in chronic myeloid leukemia.

Authors:  Alois Gratwohl; Helen Baldomero; Jakob Passweg
Journal:  Ann Hematol       Date:  2015-03-27       Impact factor: 3.673

Review 4.  A review of the European LeukemiaNet recommendations for the management of CML.

Authors:  Michele Baccarani; Fausto Castagnetti; Gabriele Gugliotta; Gianantonio Rosti
Journal:  Ann Hematol       Date:  2015-03-27       Impact factor: 3.673

5.  Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008.

Authors:  Magnus Björkholm; Lotta Ohm; Sandra Eloranta; Asa Derolf; Malin Hultcrantz; Jan Sjöberg; Therese Andersson; Martin Höglund; Johan Richter; Ola Landgren; Sigurdur Y Kristinsson; Paul W Dickman
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

Review 6.  How I treat newly diagnosed chronic phase CML.

Authors:  Jorge Cortes; Hagop Kantarjian
Journal:  Blood       Date:  2012-05-21       Impact factor: 22.113

7.  Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.

Authors:  Anna Maria Raiola; Alida Dominietto; Anna Ghiso; Carmen Di Grazia; Teresa Lamparelli; Francesca Gualandi; Stefania Bregante; Maria Teresa Van Lint; Simona Geroldi; Silvia Luchetti; Filippo Ballerini; Maurizio Miglino; Riccardo Varaldo; Andrea Bacigalupo
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-29       Impact factor: 5.742

Review 8.  Is there a best TKI for chronic phase CML?

Authors:  Richard A Larson
Journal:  Blood       Date:  2015-11-19       Impact factor: 22.113

Review 9.  How I treat newly diagnosed chronic myeloid leukemia in 2015.

Authors:  Carlo Gambacorti-Passerini; Rocco Piazza
Journal:  Am J Hematol       Date:  2014-11-24       Impact factor: 10.047

Review 10.  Treatment of chronic myelogenous leukemia.

Authors:  Christine Kujak; Jill M Kolesar
Journal:  Am J Health Syst Pharm       Date:  2016-02-01       Impact factor: 2.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.